Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451
Kawai K, Kawai AT. Racial/ethnic and socioeconomic disparities in adult vaccination coverage. Am J Prev Med. 2021 Oct;61(4):465-73. doi: 10.1016/j.amepre.2021.03.023
Forneris CA, Gartlehner G, Brownley KA, Gaynes BN, Sonis J, Coker-Schwimmer E, Jonas DE, Greenblatt A, Wilkins TM, Woodell CL, Lohr KN. Interventions to prevent post-traumatic stress disorder: a systematic review. Am J Prev Med. 2013 Jun;44(6):635-50. doi: 10.1016/j.amepre.2013.02.013
Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.
Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S. Am J Prev Med. 2009 Nov 1;37(5):381-8.
Mansfield CA, Johnson FR, Van Houtven GL. The missing piece: valuing averting behavior for children's ozone exposures. Resour Energy Econ. 2006 Aug;28(3):215-28.
Ellison RC, Rothman KJ, Zhang Y, Djousse L. Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults. Am J Prev Med. 2005 Oct 1;29(3):243.
Smith VK, Poulos C, Kim H. Treating open space as an urban amenity. Resour Energy Econ. 2002 Feb 15;24(1-2):107-29.
Spencer DL, Reed (Earnshaw) SJ, Atkinson D, Kalsbeek WD. Design of a survey to inform state health decision making: a collaborative effort. Am J Prev Med. 1997 Nov 1;13(6 Suppl):69-74.